Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Resecabtagene Autoleucel in Myasthenia Gravis: NCT06359041 Clinical Landscape Report 2026
28 September 2026
NCT06359041 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Daratumumab in Acute Chest Syndrome: NCT06358638 Clinical Landscape Report 2026
28 September 2026
NCT06358638 clinical landscape for Acute Chest Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efgartigimod Alfa in Myasthenia Gravis: NCT06298552 Clinical Landscape Report 2026
28 September 2026
NCT06298552 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Decitabine/Tetrahydrouridine in Anemia, Sickle Cell: NCT06291285 Clinical Landscape Report 2026
28 September 2026
NCT06291285 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Mitapivat in Kidney Diseases: NCT06286046 Clinical Landscape Report 2026
28 September 2026
NCT06286046 clinical landscape for Kidney Diseases: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
BRL-101 in Anemia, Sickle Cell: NCT06300723 Clinical Landscape Report 2026
28 September 2026
NCT06300723 clinical landscape for Anemia, Sickle Cell: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Parecoxib Sodium in Acute Pain: NCT06315920 Clinical Landscape Report 2026
28 September 2026
NCT06315920 clinical landscape for Acute Pain: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Rituximab in Myasthenia Gravis, Ocular: NCT06342544 Clinical Landscape Report 2026
28 September 2026
NCT06342544 clinical landscape for Myasthenia Gravis, Ocular: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CD19-BCMA Targeted CAR-T(Tangdu Hospital) in Lambert-Eaton Myasthenic Syndrome: NCT06371040 Clinical Landscape Report 2026
28 September 2026
NCT06371040 clinical landscape for Lambert-Eaton Myasthenic Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white spa…
9 min read
LTSE-2578 in Idiopathic Pulmonary Fibrosis: ACTRN12624000535572 Clinical Landscape Report 2026
28 September 2026
ACTRN12624000535572 clinical landscape for Idiopathic Pulmonary Fibrosis: endpoints, sponsor, phase, geography, readouts, asset context and development white…
9 min read
Neostigmine Methylsulfate in Myasthenia Gravis: ACTRN12624000545561 Clinical Landscape Report 2026
28 September 2026
ACTRN12624000545561 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Efgartigimod/Hyaluronidase in Myasthenia Gravis: NCT06392386 Clinical Landscape Report 2026
28 September 2026
NCT06392386 clinical landscape for Myasthenia Gravis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.